
Immunitybio Inc
NASDAQ:IBRX

Intrinsic Value
The intrinsic value of one
IBRX
stock under the Base Case scenario is
9.64
USD.
Compared to the current market price of 2.53 USD,
Immunitybio Inc
is
Undervalued by 74%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Immunitybio Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Immunitybio Inc
Balance Sheet Decomposition
Immunitybio Inc
Current Assets | 109.2m |
Cash & Short-Term Investments | 61.6m |
Receivables | 17.5m |
Other Current Assets | 30.1m |
Non-Current Assets | 194.6m |
PP&E | 167.1m |
Intangibles | 15.4m |
Other Non-Current Assets | 12.1m |
Free Cash Flow Analysis
Immunitybio Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Immunitybio Inc
Revenue
|
31.2m
USD
|
Cost of Revenue
|
-7.2m
USD
|
Gross Profit
|
24m
USD
|
Operating Expenses
|
-337.4m
USD
|
Operating Income
|
-313.4m
USD
|
Other Expenses
|
-95.7m
USD
|
Net Income
|
-409.1m
USD
|
IBRX Profitability Score
Profitability Due Diligence
Immunitybio Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Score
Immunitybio Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
IBRX Solvency Score
Solvency Due Diligence
Immunitybio Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Score
Immunitybio Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IBRX Price Targets Summary
Immunitybio Inc
According to Wall Street analysts, the average 1-year price target for
IBRX
is 11.48 USD
with a low forecast of 4.29 USD and a high forecast of 31.5 USD.
Dividends
Current shareholder yield for IBRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IBRX
stock under the Base Case scenario is
9.64
USD.
Compared to the current market price of 2.53 USD,
Immunitybio Inc
is
Undervalued by 74%.